ATE474931T1 - Epitop-synchronisierung in antigen präsentierenden zellen - Google Patents

Epitop-synchronisierung in antigen präsentierenden zellen

Info

Publication number
ATE474931T1
ATE474931T1 AT01930922T AT01930922T ATE474931T1 AT E474931 T1 ATE474931 T1 AT E474931T1 AT 01930922 T AT01930922 T AT 01930922T AT 01930922 T AT01930922 T AT 01930922T AT E474931 T1 ATE474931 T1 AT E474931T1
Authority
AT
Austria
Prior art keywords
housekeeping
disclosed
antigen
cells
presenting cells
Prior art date
Application number
AT01930922T
Other languages
English (en)
Inventor
John Simard
David Diamond
Xiang-Dong Lei
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/561,074 external-priority patent/US6861234B1/en
Application filed by Mannkind Corp filed Critical Mannkind Corp
Application granted granted Critical
Publication of ATE474931T1 publication Critical patent/ATE474931T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT01930922T 2000-04-28 2001-04-27 Epitop-synchronisierung in antigen präsentierenden zellen ATE474931T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56157200A 2000-04-28 2000-04-28
US56046500A 2000-04-28 2000-04-28
US56157100A 2000-04-28 2000-04-28
US09/561,074 US6861234B1 (en) 2000-04-28 2000-04-28 Method of epitope discovery
PCT/US2001/013806 WO2001082963A2 (en) 2000-04-28 2001-04-27 Method of identifying and producing antigen peptides and use thereof as vaccines

Publications (1)

Publication Number Publication Date
ATE474931T1 true ATE474931T1 (de) 2010-08-15

Family

ID=27504814

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01930922T ATE474931T1 (de) 2000-04-28 2001-04-27 Epitop-synchronisierung in antigen präsentierenden zellen

Country Status (13)

Country Link
US (1) US20070269464A1 (de)
EP (4) EP1276896B1 (de)
JP (1) JP2003535824A (de)
CN (1) CN1440462A (de)
AT (1) ATE474931T1 (de)
AU (3) AU5741001A (de)
CA (1) CA2405363A1 (de)
DE (1) DE60142615D1 (de)
DK (1) DK1276896T3 (de)
ES (1) ES2347762T3 (de)
HK (1) HK1053333A1 (de)
NZ (1) NZ521715A (de)
WO (1) WO2001082963A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US6773695B2 (en) 2000-10-05 2004-08-10 Mannkind Corporation Modulation of allergic response
EP1595548A3 (de) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-Neovaskulatur Präparationen zur Krebsbehandlung
EP1372736A4 (de) 2001-03-07 2004-11-17 Mannkind Corp Präparate gegen gefässneubildung bei krebs
EP1752160A3 (de) 2001-04-06 2007-05-30 Mannkind Corporation Epitop-Sequenzen
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
AU2008229888B2 (en) * 2001-11-07 2012-07-05 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
EP2314712B1 (de) 2001-11-07 2014-01-08 Mannkind Corporation Für Epitope von Antigenen kodierende Expressionsvektoren sowie Verfahren zu deren Konzeption
CN1691964A (zh) * 2002-09-06 2005-11-02 曼康公司 表位序列
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR20140067141A (ko) 2002-12-16 2014-06-03 글로브이뮨 면역 요법으로서의 효모계 백신
WO2005010190A1 (en) * 2003-07-22 2005-02-03 Ludwig Institute For Cancer Research Ssx-2 peptides presented by hla class ii molucules
MX2007008010A (es) * 2004-12-29 2007-09-07 Mannkind Corp Metodos para desviar celulas cd4+ en la induccion de una inmuno respuesta.
AU2005321898B2 (en) * 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
SG162817A1 (en) * 2005-06-17 2010-07-29 Mannkind Corp Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
WO2006138568A2 (en) * 2005-06-17 2006-12-28 Mannkind Corporation Multivalent entrain-and-amplify immunotherapeutics for carcinoma
ES2579762T3 (es) 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
EP1996716B1 (de) 2006-03-20 2011-05-11 The Regents of the University of California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
AU2007298494B2 (en) 2006-09-21 2013-09-26 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CN101246176B (zh) * 2007-02-13 2013-06-05 许洋 鳞状细胞癌抗原阴性***血清蛋白质检测的质谱试剂及其制备方法
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
WO2010096486A1 (en) 2009-02-17 2010-08-26 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
US20130224249A1 (en) * 2010-09-03 2013-08-29 Ludwig Institute For Cancer Research Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
JP2014516538A (ja) * 2011-05-26 2014-07-17 ジーニウス バイオテクノロジー インベストメンツ リミテッド ライアビリティ カンパニー 調節された免疫優勢療法
CN107817348A (zh) * 2012-09-05 2018-03-20 亚利桑那州评议委员会,亚利桑那州法人团体,代理和代表亚利桑那州立大学 发现治疗靶标的方法
KR20150130284A (ko) * 2013-03-15 2015-11-23 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 백신 및 이를 이용한 치료 방법
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
CN104761644A (zh) * 2014-01-03 2015-07-08 百奇生物科技（苏州）有限公司 大肠杆菌表达的融合蛋白mbp-mart-1及其制备和应用
CN103837688A (zh) * 2014-03-27 2014-06-04 吉林农业大学 一种检测犬猫弓形虫抗体的间接elisa试剂盒
ES2868305T3 (es) 2014-03-28 2021-10-21 Univ Washington Through Its Center For Commercialization Vacunas contra el cáncer de mama y de ovario
WO2015149010A1 (en) * 2014-03-28 2015-10-01 University Of Washington Through Its Center For Commercialization Methods of identifying antigens for vaccines
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
CN113549153A (zh) * 2014-05-29 2021-10-26 宏观基因有限公司 三特异性结合分子和其使用方法
CN104142401B (zh) * 2014-07-25 2016-04-20 北京普恩光德生物科技开发有限公司 ***相关抗原检测试剂盒
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
CN105067731B (zh) * 2015-06-05 2017-06-16 中国农业科学院兰州兽医研究所 一种弓形虫感染后血清中生物标记物的筛选方法及筛选出的生物标记物的应用
NZ739721A (en) 2015-08-07 2019-09-27 Imaginab Inc Antigen binding constructs to target molecules
CN105175498A (zh) * 2015-10-09 2015-12-23 深圳市康尔诺生物技术有限公司 一种***相关的热休克蛋白复合物及其应用
US11464839B2 (en) 2015-12-04 2022-10-11 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different MHC molecules
CA3009542C (en) * 2015-12-23 2023-08-29 Medigene Immunotherapies Gmbh Novel generation of antigen-specific tcrs
CA3028002A1 (en) * 2016-06-27 2018-01-04 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CN110809580A (zh) * 2017-01-24 2020-02-18 安贝科思生物制剂公司 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
WO2018217852A1 (en) * 2017-05-23 2018-11-29 Gettysburg College Crispr based tool for characterizing bacterial serovar diversity

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439199A (en) * 1980-02-19 1984-03-27 Alza Corporation Method for administering immunopotentiator
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5196321A (en) * 1986-10-02 1993-03-23 Massachusetts Institute Of Technology Methods for in vitro cleavage of ubiquitin fusion proteins
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
US5093242A (en) * 1986-10-02 1992-03-03 Massachusetts Institute Of Technology Methods of generating desired amino-terminal residues in proteins
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
JPH03503482A (ja) * 1988-02-12 1991-08-08 コモンウェルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガナイゼーション ポックスウイルスベクター
US6723832B1 (en) * 1996-10-03 2004-04-20 Ludwig Institute For Cancer Research Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE69033295T2 (de) 1989-11-03 2000-05-25 Donald L Morton Nachweismethode für Harnkarzinom-assoziierte Antigene
DE4143467C2 (de) * 1991-05-17 1995-02-09 Max Planck Gesellschaft Peptidmotiv und dessen Verwendung
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5744316A (en) * 1992-12-22 1998-04-28 Ludwig Institute For Cancer Research Isolated, tyrosinase derived peptides and uses thereof
US5989565A (en) 1993-01-29 1999-11-23 University Of Pittsburgh Elution and identification of T cell epitopes from viable cells
EP0689551B1 (de) * 1993-03-17 2008-02-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
AU738649B2 (en) * 1996-04-26 2001-09-20 Rijksuniversiteit Te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
EP0928688A4 (de) 1997-07-03 2000-10-18 Matsushita Electric Ind Co Ltd Tintenstrahlaufzeichnungskopf und verfahren zur herstellung
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1118860A1 (de) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Verfahren zur Auswahl und zur Herstellung von T-Zellen-Peptidepitopen sowie darauf basierten Impfstoffen
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences

Also Published As

Publication number Publication date
US20070269464A1 (en) 2007-11-22
AU2010251790A1 (en) 2011-01-06
JP2003535824A (ja) 2003-12-02
AU2001257410B9 (en) 2006-10-05
DE60142615D1 (de) 2010-09-02
WO2001082963A3 (en) 2002-04-11
AU2001257410B8 (en) 2006-12-21
NZ521715A (en) 2008-01-31
AU2010251790B2 (en) 2013-02-07
CA2405363A1 (en) 2001-11-08
EP2278023A1 (de) 2011-01-26
AU5741001A (en) 2001-11-12
EP2248910A1 (de) 2010-11-10
CN1440462A (zh) 2003-09-03
AU2001257410B2 (en) 2006-08-24
EP1276896A2 (de) 2003-01-22
EP1276896B1 (de) 2010-07-21
HK1053333A1 (en) 2003-10-17
EP2278024A1 (de) 2011-01-26
ES2347762T3 (es) 2010-11-04
DK1276896T3 (da) 2010-10-18
WO2001082963A2 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
ATE474931T1 (de) Epitop-synchronisierung in antigen präsentierenden zellen
CY1118629T1 (el) Εμβολιο ιου ερπητα ζωστηρα
NO20015073L (no) Vaksiner
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
GB2434367A (en) Improved vaccines
EA200702633A1 (ru) Вакцина против малярии
IL164812A0 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
WO2008000261A3 (en) Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails
ATE494907T1 (de) Pharmazeutische zusammensetzungen, die immunologisch aktive herpes simplex virus proteinfragmente enthalten
WO2006113622A3 (en) Direct vaccination of the bone marrow
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
BRPI0606165A2 (pt) método de indução de uma resposta imunológica de célula t de memória contra pelo menos um antìgeno em um paciente humano, uso de uma composição imunogênica que compreende um vetor de vìrus de infecção virulenta não-replicante ou emparelhado de replicação que expressa o produto de tradução de um gene de ag85a micobacterial, uso de um antìgeno na manufatura de um medicamento para o tratamento de uma doença em um paciente mediante a indução de uma resposta imunológica de célula t de memória central e vacina vetorada
WO2003078640A3 (en) Recombinant drug-sensitive vaccinia virus as smallpox vaccine
AU2003288510A1 (en) Immunizing fish against viral infection
JP2014516538A5 (de)
WO2003057823A3 (en) Epitope synchronization in antigen presenting cells
WO2002009752A3 (en) Immunological adjuvant compounds
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
DE69720065D1 (de) Therapeutische anwendungen von antigenen oder epitopen assoziert mit unvollständiger zellulärer peptidprozesierung , z.b.: exprimiert in rma-s zellen transfiziert mit b7-1 gen
ZA200706389B (en) Compositions for immunizing against mycobacterium
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
FR2796282B1 (fr) Vaccin inactive contre la calicivirose feline
ATE526035T1 (de) Tollwut-impfstoff

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties